|
Profile
|
Delegates :
Honoka Kiso |

|
Incorporated :
May 12 , 2020 |
Paid in Capital :
50 Million yen |
Employees :
15 人 |
Address :
Kajii-cho 448-5 Creation Core Kyotomikuruma 210, 211, Kamigyo-ku Kawaramachidouri Imadegawakudaru, Kyoto-si KYOTO
〒602-0841
|
TEL/FAX :
/ |
URL:
https://toregem.co.jp/en/home_en |
Attachment :
|
Mission/Background :
Toregem Bio Pharma is a startup venture from Kyoto University that was founded for the purpose of research and development and launch of tooth regeneration antibody drug based on the research results of Dr. Katsu Takahashi, Oral and Maxillofacial Surgery, Kyoto University. We first hope to treat patients with congenital tooth loss who do not grow permanent tooth buds due to genetic causes. With this treatment we provides solutions to children and their parents who visit the dental hospitals seeking treatment for congenital and other dental anomalies (like anodontia, acquired tooth defects and tooth decay). Our final goal is to offer advanced & scientifically driven clinical solution for the growth of teeth derived from their own tissues. Healthy teeth offers healthy food intake which helps in improving quality of life. We with its innovation driven drugs/therapies for tooth regeneration hopes to improve and realise a healthy and prosperous society for the people dealing with dental issues around the world. |
Technology & Business
|
Based on the mouse findings, we asked ourselves if teeth could be regenerated in humans with congenital and/or acquired tooth defects by inactivating USAG-1 protein with a drug. To test the hypothesis we used mouse anti-USAG-1 antibodies to check the biological activity of antibodies. Currently, we are humanizing three antibodies that are effective in growing teeth when administered to mice and dogs with less number of teeth. With our innovative breakthrough, we would like to introduce a tooth regeneration drug for people with tooth defects across the world. Based on the gene status, our aim is to inject one shot antibody to treat congenital or partial anodontia patients for tooth regeneration.
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
Humanizing anti-USAG-1 antibodies
|
Phase1
|
Development for treatment of anogenital anodontia, Development for treatment of missing teeth
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Alliance strategy
|
We are seeking a licensee for TRG035.
|
|
|